1. MRC Technology an independent life science medical research charity Biotech & Money 2016 Mr Andrew Mercieca, Director of Finance andrew.mercieca@tech.mrc.ac.uk www.mrctechnology.org

2. Who are MRC Technology? A UK registered charity Translating academic research Life Science specialist Founded in mid 1980s 25+ years in patenting, licensing, drug discovery and diagnostics research Key Client: UK Medical Research Council Collaborating widely UK, EC, US, China A partner in Translation

3. Products on the Market Tysabri ® Actemra ® Entyvio ® Keytruda ®

4. MRC Technology Today Ambition driven by our Charitable ‘Objects’ Promote public benefit by improving human health Assisting the progress of the scientific discoveries and new technologies Work with industry, charities, universities and health services Perform R&D as needed to accelerate the progress of scientific discoveries 148 Staff 30 in ‘Technology Transfer’ 74 ‘Drug Discovery’ scientists 10 ‘Diagnostics’ scientists Financially self sufficient Annual Revenue £28m Annual Turnover £22.4m R&D Spend Drug Discovery ~£10m Diagnostics ~£0.8m

5. What we offer ‘Translational’ Research Collaborations: Early stage drug discovery Development of diagnostic tests ‘Bridging the gap’ between blue sky research and its utilization Commercialisation Delivering therapies

6. Small Molecule Drug Discovery Team Assay Development and Screening (Highly diverse experience) HTS compatible assays, liquid handling robotics Diverse compound library >120K; focused sets Hit validation, IC 50 data Medicinal Chemistry (High level of “Pharma” experience) Hit exploration and SAR development, computational chemistry Tool compounds Lead compounds for partnering Early Pharmacology and ADME/DMPK Cell based assays using pharmacodynamic read-outs In house - Solubility, LogD, Microsomes, PAMPA, cytotoxicity PK and other studies outsourced

7. Antibody Engineering Team Capabilities Generate mouse monoclonal antibodies Humanise rodent antibodies (CDR Grafting) Antibody engineering Track record Group established 1988 55+ antibodies successfully humanized 12 recombinant antibodies into clinic 6 currently in active clinical development 4 therapeutic antibodies approved Marketed Products Tysabri ® ; Actemra ® ; Entyvio ® ; Keytruda ® Fab Fv Fc

8. Diagnostics Development Team Experienced team leader Ex-Almac Diagnostics 10+ years in the industry 5 Assay development scientists Currently recruiting Investment in new equipment & systems Liquid handling qPCR Quality Assurance Building Networks with industry and clinicians

9. Translational Collaborations Academic scientists/Institutions Exciting blue sky research; Novel target, biomarker or test Potential to address unmet clinical need Biotechnology companies early stage assets limited resources Pharmaceutical Companies Risk sharing on interesting targets with limited validation ‘Parked’ assets at ‘hit’ or ‘hit explosion’ stage

10. Projects We Are Looking For Drug Targets Novel targets or novel MOA Clear disease association Diagnostics RNA/DNA –based assays in oncology, infectious diseases and pharmacogenomics Clear disease association but limited validation A range of enabling tools including: Assays(s) and materials which may be used to validate the opportunity Disease models

11. What we will do: Drug Discovery Work with Collaborator to deliver: Composition of Matter IP 2 or more series of small molecules Potent, selective, good DMPK/ADMET properties OR, a humanised rodent mAb with high potency, expression, thermostability and low aggregation Pre-clinical proof of concept in a disease model Professional data package for commercialisation Mitigates the investment risk to industry Provides a solid platform for further pre-clinical development

12. What we will do: Diagnostics Work with Collaborator to: Translate excellent research into potential product Quality controlled materials Robust and reproducible assays and protocols Rigorous real–world testing Deliver Professional data package for commercialisation Mitigates the investment risk to industry Provides a solid platform for clinical development

13. Recent Drug Discovery Collaborations

14. Recently Partnered Projects Antibodies Immunotherapy HCV Fibrosis target Small Molecules Neurological target Melanocortin receptors (MCRs) programme

15. Current Partnering Opportunities TargetModeIndicationStatus MNK1Small MoleculeCancerLead optimisation IL-17BRAntibodyFibrosis/ Allergic Asthma Humanised Kir7.1Small Moleculepost-partum haemorrhage Screening/Hits MCR2Small MoleculeCushing’s DiseaseHit to Lead

16. MRCT: The Partner of Choice Flexible business model Proven track record Fully collaborative Flexible deal structures Academic and commercial partners Translating Together Contact andrew.mercieca@tech.mrc.ac.ukandrew.mercieca@tech.mrc.ac.uk